NCT03493178 · Early Phase 1 · ACTIVE NOT RECRUITING
Glutathione in Mild Cognitive Impairment
This trial is testing whether two dietary supplements, glycine and N-acetylcysteine (NAC), can raise glutathione levels in people with mild cognitive impairment (MCI) and whether that affects cognition. Glutathione is the body's main antioxidant, and levels tend to fall with age. It is an Early Phase 1 study, meaning this is very preliminary exploratory work — researchers are looking at mechanisms, not proving a treatment works.
Eligibility criteria
Inclusion Criteria at study entry: (1) Diagnosis of Mild Cognitive Impairment Exclusion Criteria at study entry: (1) hospitalization within past 3 months; (2) known diabetes; (3) creatinine greater than or equal to 1.5 mg/dL; (4) hemoglobin concentration less than 11 g/dL; (5) known liver disease, or AST/ALT greater than or equal to 2x ULN; (6) history of stroke, brain tumor, or active heart failure; (7) history of psychiatric disorders; (8) untreated depression.
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2026-03-24